Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $59.9000 (1.53%) ($57.0000 - $60.8800) on Wed. Oct. 17, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 9.69% (three month average) | RSI | 52 | Latest Price | $59.9000(1.53%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP advances 0.7% a day on average for past five trading days. | Weekly Trend | TNXP declines -3.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) XOP(11%) USO(10%) XLB(10%) ACES(9%) DRIV(9%) | Factors Impacting TNXP price | TNXP will decline at least -4.845% in a week (0% probabilities). TLT(-7%) SHY(-7%) SIL(-6%) GLD(-6%) GDX(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.845% (StdDev 9.69%) | Hourly BBV | 0 () | Intraday Trend | 4.2% | | | |
|
1 - 5 Day Possible Target | $46.68(-22.07%) | Resistance Level | $61.39 | 5 Day Moving Average | $57.67(3.87%) | 10 Day Moving Average | $59.74(0.27%) | 20 Day Moving Average | $61.39(-2.43%) | To recent high | -86% | To recent low | 8.9% | Market Cap | $15.874b | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |